Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of its adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.
Positive phase III trial results support the application, demonstrating immune response and tolerability in this demographic. If approved, GSK's RSV vaccine would be the first vaccine available to help protect this group.
Arexvy is currently approved in the United States in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV.
The Prescription Drug User Fee Act date for the FDA's decision is 7 June 2024.
The burden of RSV disease in adults, particularly those with conditions like COPD and asthma, is significant, with potential severe consequences such as pneumonia, underscoring the critical need for preventive measures.
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial